Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. Schirripa M, et al. Among authors: suenaga m. PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018. PLoS One. 2018. PMID: 29522543 Free PMC article.
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N. Osumi H, et al. Among authors: suenaga m. Gastric Cancer. 2016 Apr;19(2):625-630. doi: 10.1007/s10120-015-0517-9. Epub 2015 Aug 11. Gastric Cancer. 2016. PMID: 26260873 Clinical Trial.
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Okazaki S, et al. Among authors: suenaga m. Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11. Mol Cancer Ther. 2016. PMID: 27196764 Free PMC article.
Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.
Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Berger MD, et al. Among authors: suenaga m. Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696. Oncotarget. 2016. PMID: 27449091 Free PMC article.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Nakayama I, et al. Among authors: suenaga m. BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
376 results